Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim Dekermendjian

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Advances in Experimental Medicine and Biology|February 4, 2011
TRPV1: a therapy target that attracts the pharmaceutical interestsRong Xia, Kim Dekermendjian, Elke Lullau, et al.
CNS & Neurological Disorders Drug Targets|June 10, 2008
Ion channel screening technologyMichael A Dabrowski, Kim Dekermendjian, Per-Eric Lund, et al.
Assay and Drug Development Technologies|December 15, 2007
Cellular HTS assays for pharmacological characterization of Na(V)1.7 modulatorsShephali Trivedi, Kim Dekermendjian, Ronald Julien, et al.
Bioorganic & Medicinal Chemistry Letters|December 3, 2013
Discovery and optimization of Lu AF58801, a novel, selective and brain penetrant positive allosteric modulator of alpha-7 nicotinic acetylcholine receptors: attenuation of subchronic phencyclidine (PCP)-induced cognitive deficits in rats following oral administrationJørgen Eskildsen, John P Redrobe, Anette G Sams, et al.
ACS Chemical Neuroscience|June 27, 2015
Identification and electrophysiological evaluation of 2-methylbenzamide derivatives as Nav1.1 modulatorsFrançois Crestey, Kristen Frederiksen, Henrik S Jensen, et al.
The European Journal of Neuroscience|June 22, 2017
A small molecule activator of Na<sub>v</sub> 1.1 channels increases fast-spiking interneuron excitability and GABAergic transmission in vitro and has anti-convulsive effects in vivoKristen Frederiksen, Dunguo Lu, Jinhui Yang, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Advances in Experimental Medicine and Biology|February 4, 2011
TRPV1: a therapy target that attracts the pharmaceutical interestsRong Xia, Kim Dekermendjian, Elke Lullau, et al.
CNS & Neurological Disorders Drug Targets|June 10, 2008
Ion channel screening technologyMichael A Dabrowski, Kim Dekermendjian, Per-Eric Lund, et al.
Assay and Drug Development Technologies|December 15, 2007
Cellular HTS assays for pharmacological characterization of Na(V)1.7 modulatorsShephali Trivedi, Kim Dekermendjian, Ronald Julien, et al.
Bioorganic & Medicinal Chemistry Letters|December 3, 2013
Discovery and optimization of Lu AF58801, a novel, selective and brain penetrant positive allosteric modulator of alpha-7 nicotinic acetylcholine receptors: attenuation of subchronic phencyclidine (PCP)-induced cognitive deficits in rats following oral administrationJørgen Eskildsen, John P Redrobe, Anette G Sams, et al.
ACS Chemical Neuroscience|June 27, 2015
Identification and electrophysiological evaluation of 2-methylbenzamide derivatives as Nav1.1 modulatorsFrançois Crestey, Kristen Frederiksen, Henrik S Jensen, et al.
The European Journal of Neuroscience|June 22, 2017
A small molecule activator of Na<sub>v</sub> 1.1 channels increases fast-spiking interneuron excitability and GABAergic transmission in vitro and has anti-convulsive effects in vivoKristen Frederiksen, Dunguo Lu, Jinhui Yang, et al.
Pageof 1